Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025

Silence Therapeutics plc

Entered at-the-market equity offering agreement with Jefferies LLC; prior 2021 ATM agreement terminated.
Jefferies receives 3.0% commission on gross proceeds; no minimum obligation to sell ADSs.
After further tax analysis, company believes it was not a PFIC for FY 2025 (previously disclosed potential PFIC status).
Added risk factor noting PFIC classification is fact-intensive and could change; no assurance from IRS.
Legal opinion from Cooley (UK) LLP on ADS validity filed as exhibit 5.1.

item 1.01item 1.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.